Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com

Please find enclosed a Press Release on

"Dr. Reddy's Laboratories announces closure of the transaction to divest ZEMBRACE SYMTOUCH and TOSYMRATM

to Upsher-Smith Laboratories, LLC"

This is for your information.

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

Reddy's Laboratories announces closure of the transaction to divest

ZEMBRACE SYMTOUCH and

TOSYMRATM to Upsher-Smith Laboratories, LLC

Hyderabad, India and Princeton,

NJ, USA. July 20, 2019 - Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announces the closure

of the transaction with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to the satisfactory completion of all customary

closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR

Under the agreement Dr. Reddy's

sold its US and select territory rights for ZEMBRACE SYMTOUCH (sumatriptan injection) 3 mg and

TOSYMRATM (sumatriptan nasal spray) 10 mg, which were commercialized through its wholly owned subsidiary, Promius Pharma,

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed

to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &

Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services

including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas

of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates

in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,

log on to: www.drreddys.com

About Promius Pharma

LLC: Promius Pharma is a wholly-owned subsidiary of Dr. Reddy's Laboratories, one of the largest and most respected

pharmaceutical companies in the world. Promius Pharma is committed to bringing new products to market that meet patients'

needs. For more information, log on to: www.promiuspharma.com.

Smith LLC: Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and

lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, it has brought

generics and brands to a wide array of customers backed by an attentive level of service, strong industry relationships, and dedication

to uninterrupted supply. For more information, visit www.upsher-smith.com.

press release may include statements of future expectations and other forward-looking statements that are based on the management's

current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance

or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking

by reason of context, the words "may", "will", "should", "expects", "plans",

"intends", "anticipates", "believes", "estimates", "predicts", "potential",

or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may

differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance

of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity

of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive

factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions

or reorganization , including related integration issues.

The company assumes no

obligation to update any information contained herein.